All Title Author
Keywords Abstract

Primary Bladder Adenocarcinoma: A Five-Year Retrospective Clinicopathologic Study of 42 Cases in Egyptian NCI (2010-14)

DOI: 10.4236/jct.2019.101008, PP. 97-116

Keywords: Bladder Cancer, Primary, Adenocarcinoma, Bilharziasis, NCI, Egypt

Full-Text   Cite this paper   Add to My Lib


Aim: Globally, primary adenocarcinoma (AC) accounts for only 0.5% - 2% of bladder cancer (BC). Bilharziasis predisposes to AC in ~10% of BC in endemic regions. The aim was to study the clinicopathologic characteristics of this rare entity and define prognostic elements influencing disease-free (DFS) & overall survival (OS). Patients & Methods: A retrospective analysis of 42 cases of primary bladder AC presented to the National Cancer Institute of Egypt (NCI-E) during a five-year period (2010-2014), clinicopathologic profiles, management and survival were assessed. Results: The mean age was 55.5 years ± 9.77 with male predominance. Hematuria, bilharziasis & urachal type experienced in 88%, 35.7% & 4.8%, respectively. Radical surgery was employed in 64.3%. Metastatic disease (stageIVB) found in 14.3%,


[1]  Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Parkin, D.M., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.
[2]  Mostafa, M.H., Sheweita, S.A. and O’Connor, P.J. (1999) Relationship between Schistosomiasis and Bladder Cancer. Clinical Microbiology Review, 12, 97-111.
[3]  Thomas, D.C., Ward, A.M. and Williams, J.L. (1971) A Study of 52 Cases of Adenocarcinoma of the Bladder. British Journal of Urology, 43, 4-15.
[4]  Burnett, A.L., Epstein, J.I. and Marshall, F.F. (1991) Adenocarcinoma of Urinary Bladder: Classification and Management. Urology, 37, 315-321.
[5]  Grignon, D.J., Ro, J.Y., Ayala, A.G., Johnson, D.E. and Ordónez, N.G. (1991) Primary Adenocarcinoma of the Urinary Bladder. A Clinicopathologic Analysis of 72 Cases. Cancer, 67, 2165-2172.<2165::AID-CNCR2820670827>3.0.CO;2-M
[6]  El-Bolkainy, M.N. (2016) Epidemiology of Cancer. In: El-Bolkainy, M.N., Nouh, M.A., Gouda, I., El-Bolkainy, T.N. and Badawy, O.M., (Eds.), Pathology of Cancer, 5th Edition, NCI-E Publication, Cairo, Egypt, 15-31.
[7]  Khorshed, E. (2016) Urinary System Tumors. In: Mokhtar, N., Asmaa, S., Badawy, O., Khorshed, E., Mohamed, G., Ibrahim, M., et al., Eds., Cancer Pathology Registry 2000-2011, Cairo Press, Cairo, Egypt, 60-74.
[8]  Burger, M., Catto, J.W., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P., et al. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63, 234-241.
[9]  El-Mekresh, M.M., El-Baz, M.A., Abol-Enein, H. and Ghoneim, M.A. (1998) Primary Adenocarcinoma of the Urinary Bladder: A Report of 185 Cases. British Journal of Urology, 82, 206-212.
[10]  Ghoneim, M.A., Abdel-Latif, M., El-Mekresh, M., Abol-Enein, H., Mosbah, A., Ashamallah, A. and ElBaz, M.A. (2008) Radical Cystectomy for Carcinoma of the Bladder: 2,720 Consecutive Cases 5 Years Later. Journal of Urology, 180, 121-127.
[11]  Epstein, J.I., Amin, M.B. and Reuter, V.E. (2010) Glandular Lesions. In: Epstein, J.I., Amin, M.B. and Reuter, V.E., Eds., Biopsy Interpretation of the Bladder, 2nd Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 180-213.
[12]  Melicow, M.M. (1955) Tumors of the Urinary Bladder: A Clinico-Pathological Analysis of over 2500 Specimens and Biopsies. Journal of Urology, 74, 498-521.
[13]  Gopalan, A., Sharp, D.S., Fine, S.W., Tickoo, S.K., Herr, H.W., Reuter, V.E. and Olgac, S. (2009) Urachal Carcinoma. The American Journal of Surgical Pathology, 33, 659-668.
[14]  Dadhania, V., Czerniak, B. and Guo, C.C. (2015) Adenocarcinoma of the Urinary Bladder. American Journal of Clinical and Experimental Urology, 3, 51-63.
[15]  Bates, A.W. and Baithun, S.I. (2000) Secondary Neoplasms of the Bladder Are Histological Mimics of Nontransitional Cell Primary Tumours: Clinicopathological and Histological Features of 282 Cases. Histopathology, 36, 32-40.
[16]  Wilson, T.G., Pritchett, T.R., Lieskovsky, G., Warner, N.E. and Skinner, D.G. (1991) Primary Adenocarcinoma of Bladder. Urology, 38, 223-226.
[17]  Zaghloul, M.S., Nouh, A., Nazmy, M., Ramzy, S., Zaghloul, A.S., Sedira, M.A. and Khalil, E. (2006) Long Term Results of Primary Adenocarcinoma of the Urinary Bladder: A Report on 192 Patients. Urologic Oncology, 24, 13-20.
[18]  Rogers, C.G., Palapattu, G.S., Shariat, S.F., Karakiewicz, P.I., Bastian, P.J., Lotan, Y., et al. (2006) Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. Journal of Urology, 175, 2048-2053.
[19]  Black, P.C., Brown, G.A. and Dinney, C.P. (2009) The Impact of Variant Histology on the Outcome of Bladder Cancer Treated with Curative Intent. Urologic Oncology, 27, 3-7.
[20]  Porten, S.P., Willis, D. and Kamat, A.M. (2014) Variant Histology, Role in Management and Prognosis of Nonmuscle Invasive Bladder Cancer. Current Opinion in Urology, 24, 517-523.
[21]  Williams, C.R. and Chavda, K. (2015) En Bloc Robot-Assisted Laparoscopic Partial Cystectomy, Urachal Resection, and Pelvic Lymphadenectomy for Urachal Adenocarcinoma. Reviews in Urology, 17, 46-49.
[22]  Makar, N. (1962) Some Observations on Pseudoglandular Proliferation in the Bilharzial Bladder. Acta Union Internationalis Contra Cancer, 18, 599-602.
[23]  Fiter, L., Gimeno, F., Martin, L. and Gomez Tejeda, L. (1993) Signet-Ring Adenocarcinoma of the Bladder. Urology, 41, 30-33.
[24]  Xu, W., Yu, B., Xu, T., Xu, Z., Cai, H. and Zou. Q. (2015) Chemotherapy for Primary Adenocarcinoma of the Urinary Bladder, Case Report. Advances in Pharmacoepidemiology & Drug Safety, 4, 180.
[25]  Logothetis, C.J., Samuels, M.L. and Ogden, S. (1985) Chemotherapy for Adenocarcinomas of Bladder and Urachal Origin, 5-Fluorouracil, Doxorubicin, and Mitomycin-C. Urology, 26, 252-255.
[26]  Siefker-Radtke, A.O., Gee, J., Shen, Y., Wen, S., Daliani, D., Millikan, R.E. and Pisters, L.L. (2003) Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center Experience. Journal of Urology, 169, 1295-1298.
[27]  Calabrò, F. and Sternberg, C.N. (2009) Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. European Urology, 55, 348-358.
[28]  Clark, P.E. (2009) Neoadjuvant versus Adjuvant Chemotherapy for Muscleinvasive Bladder Cancer. Expert Review of Anticancer Therapy, 9, 821-830.
[29]  Dahm, P. and Gschwend, J.E. (2003) Malignant Non-Urothelial Neoplasms of the Urinary Bladder: A Review. European Urology, 44, 672-681.
[30]  Ghoneim, M.A., El-Mekresh, M.M., El-Baz, M.A., El-Attar, I.A. and Ashamallah, A. (1997) Radical Cystectomy for Carcinoma of the Bladder, Critical Evaluation of the Results in 1026 Cases. Journal of Urology, 158, 393-399.
[31]  Herr, H.W., Bochner, B.H., Sharp, P., Dalbagni, G. and Reuter, V.E. (2007) Urachal Carcinoma, Contemporary Surgical Outcomes. Journal of Urology, 178, 74-78.
[32]  John, N., Guido Sauter, E., Epstein, J.I. and Sesterhenn, I.A. (2004) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours, International Agency for Research on Cancer (IARC), Lyon.
[33]  Amin, M.B., Edge, S., Greene, F.L., Byrd, D.R., Brookland, R.K., Washington, M.K., et al. (2017) AJCC Cancer Staging Manual. 8th Edition, Springer International Publishing, Switzerland.
[34]  Eisenhauera, E.A., Therasseb, P., Bogaertsc, J., Schwartzd, L.H., Sargente, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours, Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
[35]  Korkes, K., Presti, M., Korkes, F. and Castro, M.G. (2009) Long-Term Follow-Up of Advanced Bladder Adenocarcinoma. Einstein, 7, 485-487.
[36]  Johansson, S.L. and Cohen, S.M. (1997) Epidemiology and Etiology of Bladder Cancer. Seminars in Surgical Oncology, 13, 291-298.<291::AID-SSU2>3.0.CO;2-8
[37]  El Bolkainy, M.N., Mokhtar, N.M., Ghoneim, M.A. and Hussein, M.H. (1981) The Impact of Schistosomiasis on the Pathology of Bladder Carcinoma. Cancer, 48, 2643-2648.<2643::AID-CNCR2820481216>3.0.CO;2-C
[38]  Zaghloul, M.S., Awwad, H.K., Omar, S., et al. (1992) Postoperative Radiotherapy of Carcinoma in Bilharzial Bladder. Improved Disease-Free Survival through Improving Local Control. International Journal of Radiation Oncology, Biology, Physics, 22, 511-517.
[39]  El-Bolkainy, M.N., Ghoneim, M.A. and Mansour, M.A. (1972) Carcinoma of the Bilharzial Bladder in Egypt, Clinical and Pathological Features. British Journal of Urology, 44, 561-570.
[40]  Mostofi, F.K. (1954) Potentialities of Bladder Epithelium. Journal of Urology, 71, 705-714.
[41]  El-Bolkainy, M.N. (1983) Schistosomiasis and Bladder Cancer. In: Cohen, S.M. and Bryan, C.T., Eds., The Pathology of Bladder Cancer, CRC Press, Boca Raton, Vol. 1, 57-89.
[42]  Young, J.L., Percy, C.L., Asir, A., Berg, J.W., Gusano, M.M., Gloeckler, L.A., Horm, J.W., Lourie, W.I., Pollack, E.S. and Shambaugh, E.M. (1981) The SEER Program, Cancer Incidence and Mortality, 1973-77. Nati. Cancer Inst. Monogr., 57, 1-1082.
[43]  Jacobo, E., Loening, S., Schmidt, J.D. and Culp, D.A. (1977) Primary Adenocarcinoma of the Bladder. Journal of Urology, 17, 54-56.
[44]  Bartsch, G.C., Kuefer, R., Gschwend, J.E., de Petriconi, R., Hautmann, R.E. and Volkmer, B.G. (2007) Hydronephrosis as a Prognostic Marker in Bladder Cancer in a Cystectomy-Only Series. European Urology, 51, 690-697.
[45]  Lin, H.Y., Wang, S.Z., Chen, J.X., Chen, L.W. and Xiao. J. (2011) The Prognostic Value of Hydronephrosis in Bladder Cancer Treated by Radical Cystectomy. Urologia, 78, 17-21.
[46]  Dandekar, N.P., Dalal, A.V., Tongaonkar, H.B. and Kamat, M.R. (1997) Adenocarcinoma of Bladder. European Journal of Surgical Oncology, 23, 157-160.
[47]  Holmang, S., Borghede, G. and Johansson. S.L. (1997) Primary Signet-Ring Cell Carcinoma of the Bladder: A Report on 10 Cases. Scandinavian Journal of Urology and Nephrology, 31, 145-148.
[48]  Yanagihara, Y., Tanji, N., Miura, N., Shirato, A., Nishimura, K., Fukumoto, T., Azuma, K., Miyauchi, Y., Kikugawa, T. and Yokoyama, M. (2013) Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer. Chemotherapy, 59, 402-406.
[49]  Fan, F.S. and Yang, C.-F. (2018) Advanced Primary Nonurachal Adenocarcinoma of Urinary Bladder Responding to Modified FOLFOX6 and Capecitabine: A Case Report. Oxford Medical Case Reports, 8, 256-260.


comments powered by Disqus

Contact Us


微信:OALib Journal